Evidence map›Paper›PMID 26094938›Full record

GuidelineClinical pharmacology and therapeutics2016

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Y Saito, L K Stamp, K E Caudle, M S Hershfield, E M McDonagh, J T Callaghan, W Tassaneeyakul, T Mushiroda, N Kamatani, B R Goldspiel and 4 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Trial
  8. Review
  9. Review
  10. Article
  11. External Quality Assessment of Molecular Testing forDiagnostics (Basel, Switzerland) · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025
    Review
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Y SaitoDivision of Medicinal Safety Science, National Institute of Health Sciences, Kamiyoga, Setagaya, Tokyo, Japan.
L K StampDepartment of Medicine, University of Otago, Christchurch, New Zealand.
K E CaudleDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
M S HershfieldDepartments of Medicine and Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
E M McDonaghDepartment of Genetics, Stanford University Medical Center, Stanford, California, USA.
J T CallaghanACOS for Research, Department of Veterans Affairs Medical Center, Indianapolis, Indiana, USA.
W TassaneeyakulDepartment of Pharmacology, Research and Diagnostic Center for Emerging Infectious Diseases, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
T MushirodaLaboratory for Pharmacogenetics, RIKEN, Center for Genomic Medicine, Yokohama, Japan.
N KamataniInstitute of Data Analysis, StaGen, Tokyo, Japan.
B R GoldspielPharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
E J PhillipsDivision of Infectious Diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia.
T E KleinDepartment of Genetics, Stanford University Medical Center, Stanford, California, USA.
M T M LeeLaboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Clinical Pharmacogenetics Implementation Consortium

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Clinical Pharmacogenetics Implementation Consortium (CPIC)R24GM115264 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLEIN, TERI ELLEN, RELLING, MARY V · 2015 to 2017
$3.6M
NHLBI NIH HHS U01 HL0105198NHLBI NIH HHS U01 HL105198NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIGMS NIH HHS R24 GM61374NIGMS NIH HHS U01 GM092666NIGMS NIH HHS UO1 GM92666
6 · The paper itself

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

Indexed as

Biomarkers, PharmacologicalAllopurinolDrug Administration ScheduleGenotypeGuidelines as TopicHLA-B AntigensHumansAllopurinolBiomarkers, PharmacologicalHLA-B Antigens

Identifiers

PMID26094938
PMCPMC4675696

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.